[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study
2008; Lippincott Williams & Wilkins; Volume: 180; Issue: 2 Linguagem: Inglês
10.1016/j.juro.2008.04.015
ISSN1527-3792
AutoresLori J. Sokoll, Yinghui Wang, Ziding Feng, Jacob Kagan, Alan W. Partin, Martin G. Sanda, Ian M. Thompson, Daniel W. Chan,
Tópico(s)Molecular Biology Techniques and Applications
ResumoNo AccessJournal of UrologyAdult Urology1 Aug 2008[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study Lori J. Sokoll, Yinghui Wang, Ziding Feng, Jacob Kagan, Alan W. Partin, Martin G. Sanda, Ian M. Thompson, and Daniel W. Chan Lori J. SokollLori J. Sokoll Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author , Yinghui WangYinghui Wang Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , Ziding FengZiding Feng Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , Jacob KaganJacob Kagan Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland More articles by this author , Alan W. PartinAlan W. Partin Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author , Martin G. SandaMartin G. Sanda Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts More articles by this author , Ian M. ThompsonIan M. Thompson Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Financial interest and/or other relationship with Mission Pharmacal, Veridex, Ortho Clinical Diagnostics, Societe International d'Urologie, Dannemiller Foundation, National Cancer Institute, Centers for Disease Control and Prevention, Amgen, Southwest Oncology Group, AstraZeneca and Abbott. More articles by this author , and Daniel W. ChanDaniel W. Chan Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2008.04.015AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy. Materials and Methods: Serum was collected before biopsy from 123 men with no prior biopsy or prostate cancer history. Specimens (cancer cases 51%, noncancer controls 49%) were selected equally from the 3 sites, and analyzed for prostate specific antigen, free prostate specific antigen, [-2]proenzyme prostate specific antigen, benign prostate specific antigen and testosterone (Beckman Coulter ACCESS® analyzer). Results: There was no difference in total prostate specific antigen concentrations (noncancer 6.80 ± 5.20 ng/ml, cancer 6.94 ± 5.12 ng/ml) among the groups. Overall %[-2]proenzyme prostate specific antigen had the greatest area under the curve (AUC 0.69) followed by percent free prostate specific antigen (AUC 0.61). For %[-2]proenzyme prostate specific antigen maximal sensitivity was 60% and specificity was 70%. A logistic regression model combining prostate specific antigen, benign prostate specific antigen, percent free prostate specific antigen, %[-2]proenzyme prostate specific antigen, [-2]proenzyme prostate specific antigen/benign prostate specific antigen and testosterone had an AUC of 0.73. In the 2 to 10 ng/ml prostate specific antigen range %[-2]proenzyme prostate specific antigen and the model had the largest AUC (0.73). The AUC for percent free prostate specific antigen was 0.53. Specificities for %[-2]proenzyme prostate specific antigen, the logistic regression model and percent free prostate specific antigen at 90% sensitivity were 41%, 32% and 18%, and at 95% sensitivity were 31%, 26% and 16%, respectively. Conclusions: %[-2]proenzyme prostate specific antigen was the best predictor of prostate cancer detection compared to percent free prostate specific antigen, particularly in the 2 to 10 ng/ml total prostate specific antigen range. These findings provide a rationale for broader validation studies to determine whether %[-2]proenzyme prostate specific antigen alone can replace other molecular prostate specific antigen assays (such as percent free prostate specific antigen) for improving the accuracy of prostate cancer early detection. These findings also support the usefulness of well characterized, carefully collected reference sets to evaluate new biomarkers. References 1 : Free prostate-specific antigen in serum is becoming more complex. Urology2002; 59: 797. Google Scholar 2 : A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res2000; 60: 756. Google Scholar 3 : Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem2004; 50: 1017. Google Scholar 4 : “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology2000; 55: 41. Google Scholar 5 : Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem1995; 41: 1567. Google Scholar 6 : Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology2003; 62: 177. Google Scholar 7 : Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol2003; 170: 2181. Link, Google Scholar 8 : Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol2003; 170: 723. Link, Google Scholar 9 : Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol2005; 23: 16. Google Scholar 10 : Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis. Urology2003; 61: 274. Google Scholar 11 : Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol2004; 171: 2239. Link, Google Scholar 12 : Additional use of [-2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer. Urology2005; 65: 926. Google Scholar 13 : Analytical performance of the Access BPH-A assay from Beckman Coulter. Clin Chem2006; 52: E48. Google Scholar 14 : Measuring [-2]proPSA in serum: analytical performance of the Access p2PSA assay from Beckman Coulter. Clin Chem2007; 52: A178. Google Scholar 15 : Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA1995; 274: 1214. Google Scholar 16 : Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol2003; 170: 1787. Link, Google Scholar 17 : The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int2004; 93: 720. Google Scholar 18 : A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol2005; 174: 2150. Link, Google Scholar 19 : A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur Urol2006; 50: 1014. Google Scholar 20 : Pooling of case specimens to create standard serum sets for screening cancer biomarkers. Cancer Epidemiol Biomarkers Prev2007; 16: 334. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetailsCited byStephan C, Lein M, Matalon J, Kilic E, Zhao Z, Busch J and Jung K (2018) Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health IndexJournal of Urology, VOL. 196, NO. 3, (709-714), Online publication date: 1-Sep-2016.de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D, Siddiqui J, Mosquera J, Rubin M and Sanda M (2018) Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve MenJournal of Urology, VOL. 194, NO. 1, (65-72), Online publication date: 1-Jul-2015.Lucarelli G, Rutigliano M, Bettocchi C, Palazzo S, Vavallo A, Galleggiante V, Trabucco S, Di Clemente D, Selvaggi F, Battaglia M and Ditonno P (2018) Spondin-2, a Secreted Extracellular Matrix Protein, is a Novel Diagnostic Biomarker for Prostate CancerJournal of Urology, VOL. 190, NO. 6, (2271-2277), Online publication date: 1-Dec-2013.Tosoian J, Loeb S, Feng Z, Isharwal S, Landis P, Elliot D, Veltri R, Epstein J, Partin A, Carter H, Trock B and Sokoll L (2018) Association of [−2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate CancerJournal of Urology, VOL. 188, NO. 4, (1131-1136), Online publication date: 1-Oct-2012.Liang Y, Ankerst D, Ketchum N, Ercole B, Shah G, Shaughnessy J, Leach R and Thompson I (2018) Prospective Evaluation of Operating Characteristics of Prostate Cancer Detection BiomarkersJournal of Urology, VOL. 185, NO. 1, (104-110), Online publication date: 1-Jan-2011.Catalona W, Partin A, Sanda M, Wei J, Klee G, Bangma C, Slawin K, Marks L, Loeb S, Broyles D, Shin S, Cruz A, Chan D, Sokoll L, Roberts W, van Schaik R and Mizrahi I (2018) A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen RangeJournal of Urology, VOL. 185, NO. 5, (1650-1655), Online publication date: 1-May-2011.Le B, Griffin C, Loeb S, Carvalhal G, Kan D, Baumann N and Catalona W (2018) [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening StudyJournal of Urology, VOL. 183, NO. 4, (1355-1359), Online publication date: 1-Apr-2010. Volume 180Issue 2August 2008Page: 539-543 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordstumor markersprostatic neoplasmsbiologicalearly diagnosisprostate-specific antigenAcknowledgmentsBeckman Coulter, Inc. provided analysis of the samples in this study.MetricsAuthor Information Lori J. Sokoll Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Yinghui Wang Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Ziding Feng Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Jacob Kagan Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland More articles by this author Alan W. Partin Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Martin G. Sanda Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts More articles by this author Ian M. Thompson Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas Financial interest and/or other relationship with Mission Pharmacal, Veridex, Ortho Clinical Diagnostics, Societe International d'Urologie, Dannemiller Foundation, National Cancer Institute, Centers for Disease Control and Prevention, Amgen, Southwest Oncology Group, AstraZeneca and Abbott. More articles by this author Daniel W. Chan Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)